Clinical Trial Update: RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports termination of a study evaluating eltrombopag to reverse poor graft function after allogeneic hematopoietic cell transplantati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Failure
• Leukemia

Drugs mentioned

• Eltrombopag (eltrombopag)

Snippet

Sponsor: University Hospital, Lille | Conditions: Leukemia, Graft Failure | Phase 2 | Status: TERMINATED